Cefepime dihydrochloride (CAS 107648-80-6)

Cefepime dihydrochloride, a fourth-generation cephalosporin antibiotic, has garnered significant attention in scientific research due to its broad-spectrum antimicrobial activity and unique mechanism of action. This compound acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), particularly PBP-1A and PBP-1B, resulting in the disruption of peptidoglycan cross-linking and subsequent cell lysis. Additionally, cefepime demonstrates enhanced stability against β-lactamases, including extended-spectrum β-lactamases (ESBLs) and AmpC enzymes, which are common mechanisms of bacterial resistance. In research settings, cefepime dihydrochloride has been extensively utilized to investigate antimicrobial resistance patterns, bacterial susceptibility profiles, and mechanisms of antibiotic resistance, facilitating the development of novel strategies and antimicrobial agents. Furthermore, studies have explored the pharmacokinetics and pharmacodynamics of cefepime dihydrochloride, aiming to optimize dosing regimens and enhance its efficacy against multidrug-resistant pathogens. Beyond its antimicrobial properties, cefepime dihydrochloride has also been investigated for its immunomodulatory effects and potential applications in the management of bacterial infections associated with immune dysregulation. Overall, the versatile antimicrobial activity and unique mechanism of action of cefepime dihydrochloride make it a valuable tool in research aimed at combating antibiotic-resistant bacteria and understanding the intricacies of bacterial cell wall synthesis and resistance mechanisms.